Member Info for noix

I stand to be corrected but I don't believe any of those companies had a similar drug pipeline to that of Destiny or as advanced. But you are right it's a high risk business and as I said earlier, operating in two depressed markets - UK Pharma and AIM.

Seems a strange way to raise funds after releasing news that decimates the share price and in the wake of saying your cash runway is first quarter of 2025.

Well, unfortunately you can forget support at 48p. Next resistance is 44p and after that doesn't bear thinking about.

I disagree on the release of the news and as XF 73 dermal was positive I assume (always dangerous) you are referring to the M3 news. I honestly cannot see how they couldn't release it, as it is clearly market sensitive but I cannot understand such a fall in the sp unless it's just a sign of the awful market we are trading in and of course the constant seller doesn't help.

Re a quiet board, no names no pack drill, but there are a few bulls conspicuous by their absence since the rns.

That is of course their prerogative :)

That could explain why he went to BioTech Showcase in San Francisco and is attending Bio-Europe in the Spring.

Komakino

I believe it's flagged government approval as the main (not necessarily the only) sticking point.

I'd like to think that pretty firm verbal assurances have been given, otherwise why prolong the agony.

They said this in the rns of 12/12/22 announcing the SPA :

"The Transaction is conditional upon the satisfaction of certain conditions precedent including, inter alia, approval of the Government of the Republic of South Sudan, the approval of Savannah's shareholders and re-admission to trading on AIM taking effect."

In any of the extensions (updates) since, approval of the government of SS doesn't figure, until todays rns when this is included " whilst it continues to advance the various workstreams, including receipt of in-country approvals,"

One can draw ones own conclusions.

Bantham

We differ again. I believe it is down to the facts. The markets do not like delays and perceived uncertainty.

But if the overall deal is intact and there is a stronger product (s) in the pipeline , these setbacks just present buying opportunities.

ATB

"Share the new data set" , which you said in your first post is totally different to "announce this positive data set".

That's all they have done, announced positive results but not published the data set that goes with it.

Bill Love said nothing of the sort in today's rns.

Some friendly advice, if you are going to quote officers of the Company then do it properly in quote marks and word for word.

Bantham

Thanks for the reply. We all interpret things differently.

You have narrowed your "problem" to the NTCD-M3 news.

Firstly any delay is not good news short term but if the delay means that we have a better end product, then not withstanding the delay, that has to be overall good news.

Once Tovey got his feet under the desk he presumably did a review of operations and identified that the manufacturing process for NTCD-M3 could be improved and the board in consultation with Sebela agreed that this is the best route. This will lead to a delay and may entail a further phase 2 study before proceeding to stage 3. We should not lose sight of the fact that it achieved very good phase 2 results in liquid form and given the change should perform equally as well, if not better in tablet form, other wise why change it. It works very well.

Again with respect, I fail to see how you can say it has not been "spelled out" when you have posted the same facts in your comment.

You may not like the facts and the tone of the release but to say that it's not clear to my mind doesn't hold water.

That begs the question, what wasn't said clearly and what did you not understand.

Without wishing to sound patronising, I found it very clear and understood what was said completely.

I'd be only to happy to help with any areas of confusion if I can.

With respect, what more did you need explaining.

XF-73 passed the NIAID study with flying colours and can now advance to clinical evaluation for the treatment of Diabetic Foot infections and serious burn wound infections. The XF-73 platform continues to move forward.

As we were reminded, they flagged up possible changes to the Chemistry, Manufacturing and Controls programme for NTCD-M3 in the interims statement in September and this has now become a reality, resulting in an improved product.

There's obviously much going on behind the scenes and the new management team are not going to release any information to market which might compromise on going discussions on XF-73 nasal.

I personally do not have a problem with that, confident that the board is working to get the very best deal for the Company's shareholders, in seeking partners for this ground breaking new class of medicines.

I've put every permutation I can think of into the NIAID search engine, including the rather long pre clinical study reference number and came up with zilch.

And I believe because it's pre clinical, that's the reason, together with perhaps market sensibilities.

Tatty

Apologies if you have seen this before but the rns of July of last year gives some compelling data on the efficacy of XF-73 dermal. It's worth noting that it's addressing a market valued at $3.5 billion in 2022.

https://www.investegate.co.uk/announcement/rns/destiny-pharma--dest/publication-of-new-data-for-xf-73-/7665636

And there was me expecting you to give the exact date.

Good morning scotpak and thank you very much for your update on the Nigerian situation and in particular the currency aspect.

Let's hope we continue in the same direction. We don't need any further shocks to the core business

Scotpak

Given your expertise on the topic any new thoughts on the Nigerian business and more particularly the Naira situation ?

Ta komak, I was just about to post the same having put my earlier post up without researching the Harbour/Wintershall deal.

It's not one rule for them and one rule for us :)

A reverse takeover is, essentially, an acquisition by a listed company or its subsidiary of a business, company or assets (target) where the size of the target is larger than the listed company itself or which would result in a fundamental change in the business, the board or voting control of the listed company.

With us it has been, with Harbour and Seplat it hasn't.

All the selling ?

I make it just under 110,000 shares traded today - about £80 grands worth.

I've already made my thoughts known on the seller and take their share out of today's trades (and all the other days as well) and the sell column is negligible. It will not go on for ever and in any case, news could land anytime the market is open for business.